Novartis Case Tests India's IP Climate
By Erin Marie Daly ( January 10, 2007, 12:00 AM EST) -- Novartis AG's ongoing battle to patent its cancer treatment Gleevec in India has seen the drug maker challenge not only the rejection of its patent application earlier this year, but a key section of India's recently enacted patent laws – a maneuver that intellectual property lawyers say could be a litmus test for multinational pharmaceutical companies testing legal waters in the country....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.